Gene

TACC3

transforming acidic coiled-coil containing protein 3

Explore in graph →CI-GENE-00034443HGNC:11524 ENSG00000013810 NCBI 10460 Cancer geneApproved

Curated evidence

Clinical evidence (11)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–11 of 11 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
TACC3 Fusion1
Pazopanib + PonatinibSequential	Cholangiocarcinoma	Predictive	C	Supports Sensitivity Response	3	accepted

Cohorts

Alteration frequency by cohort (0)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

Data not yet available

No cohort frequency recorded for this gene.

Literature

Linked publications (5)

25 per page, newest first.

pubmedPublishedShowing 1–5 of 5 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.
· J Clin Oncol · 2015 · PMID 26324363 · validated civic_curation pubmed
Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer.
· Cancer Discov · 2023 · PMID 37377403 · validated civic_curation pubmed
Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.
· PLoS Genet · 2014 · PMID 24550739 · validated civic_curation pubmed
Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.
· Cancer Discov · 2018 · PMID 29848605

TACC3 Fusion8
Unspecified therapy	Esophageal Squamous Cell CarcinomaALIAS	Predictive	B	Does Not Support Sensitivity Response	3	rejected	EID2962 In this report, Mizukami et al. explored major FGFR1, FGFR2, and FGFR3 fusion transcripts in ESCC and GC specimens (n = 74 and 114, respectively) using a most comprehensive next-generation sequencing … (full text at CIViC) PMID 27771611 · Mizukami et al., 2017 · Open in CIViC	civic
Erdafitinib	Malignant NeoplasmALIAS	Predictive	B	Supports Sensitivity Response	3	accepted	EID1919 Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 5 … (full text at CIViC) PMID 26324363 · Tabernero et al., 2015 · Open in CIViC	civic
〃	GlioblastomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	2	accepted	EID13165 In the phase II NCI-MATCH EAY131-K2 trial, two patients with WHO grade IV IDH1/2-wildtype glioblastoma harboring FGFR3 fusions experienced progression-free survival exceeding 168 days during erdafitin… (full text at CIViC) PMID 38603650 · Gong et al., 2024 · Open in CIViC	civic
Fexagratinib	Renal Pelvis Urothelial CarcinomaALIAS	Predictive	C	Supports Sensitivity Response	1	submitted	EID9227 Phase II study (NCT02465060) from NCI-MATCH Trial (EAY131) Subprotocol W addressed the use of AZD4547 (an FGFR 1-3 inhibitor) in 48 tumor patients carrying FGFR 1-3 variants. Partial responses were ob… (full text at CIViC) PMID 32463741 · Chae et al., 2020 · Open in CIViC	civic
〃	Cervical Squamous Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	1	submitted	EID9241 Phase II study (NCT02465060) from NCI-MATCH Trial (EAY131) Subprotocol W addressed the use of AZD4547 (an FGFR 1-3 inhibitor) in 48 tumor patients carrying FGFR 1-3 variants. Partial responses were ob… (full text at CIViC) PMID 32463741 · Chae et al., 2020 · Open in CIViC	civic
〃	Diffuse AstrocytomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	1	submitted	EID9242 Phase II study (NCT02465060) from NCI-MATCH Trial (EAY131) Subprotocol W addressed the use of AZD4547 (an FGFR 1-3 inhibitor) in 48 tumor patients carrying FGFR 1-3 variants. Partial responses were ob… (full text at CIViC) PMID 32463741 · Chae et al., 2020 · Open in CIViC	civic
Futibatinib	Gastric Adenocarcinoma	Predictive	C	Supports Sensitivity Response	1	submitted	EID11638 In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC) PMID 34551969 · Meric-Bernstam et al., 2022 · Open in CIViC	civic
Infigratinib	Transitional Cell Carcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID6409 In this one-arm study, 67 patients with metastastic urothelial carcinoma and diverse FGFR3 alterations were treated with pan-FGFR Inhibitor BGJ398. The majority of patients (70.1%) had received two or… (full text at CIViC) PMID 29848605 · Pal et al., 2018 · Open in CIViC	civic

TACC3 Fusion8

Unspecified therapy

Esophageal Squamous Cell CarcinomaALIAS

Predictive

Does Not Support Sensitivity Response

rejected

EID2962

In this report, Mizukami et al. explored major FGFR1, FGFR2, and FGFR3 fusion transcripts in ESCC and GC specimens (n = 74 and 114, respectively) using a most comprehensive next-generation sequencing … (full text at CIViC)

PMID 27771611 · Mizukami et al., 2017 · Open in CIViC

civic

Erdafitinib

Malignant NeoplasmALIAS

Predictive

Supports Sensitivity Response

accepted

EID1919

Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 5 … (full text at CIViC)

PMID 26324363 · Tabernero et al., 2015 · Open in CIViC

civic

〃

GlioblastomaCURATED_BROADER

Predictive

Supports Sensitivity Response

accepted

EID13165

In the phase II NCI-MATCH EAY131-K2 trial, two patients with WHO grade IV IDH1/2-wildtype glioblastoma harboring FGFR3 fusions experienced progression-free survival exceeding 168 days during erdafitin… (full text at CIViC)

PMID 38603650 · Gong et al., 2024 · Open in CIViC

civic

Fexagratinib

Renal Pelvis Urothelial CarcinomaALIAS

Predictive

Supports Sensitivity Response

submitted

EID9227

Phase II study (NCT02465060) from NCI-MATCH Trial (EAY131) Subprotocol W addressed the use of AZD4547 (an FGFR 1-3 inhibitor) in 48 tumor patients carrying FGFR 1-3 variants. Partial responses were ob… (full text at CIViC)

PMID 32463741 · Chae et al., 2020 · Open in CIViC

civic

〃

Cervical Squamous Cell CarcinomaCURATED_BROADER

Predictive

Supports Sensitivity Response

submitted

EID9241

PMID 32463741 · Chae et al., 2020 · Open in CIViC

civic

〃

Diffuse AstrocytomaCURATED_BROADER

Predictive

Supports Sensitivity Response

submitted

EID9242

PMID 32463741 · Chae et al., 2020 · Open in CIViC

civic

Futibatinib

Gastric Adenocarcinoma

Predictive

Supports Sensitivity Response

submitted

EID11638

In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC)

PMID 34551969 · Meric-Bernstam et al., 2022 · Open in CIViC

civic

Infigratinib

Transitional Cell Carcinoma

Predictive

Supports Sensitivity Response

accepted

EID6409

In this one-arm study, 67 patients with metastastic urothelial carcinoma and diverse FGFR3 alterations were treated with pan-FGFR Inhibitor BGJ398. The majority of patients (70.1%) had received two or… (full text at CIViC)

PMID 29848605 · Pal et al., 2018 · Open in CIViC

civic

CCDC6 Fusion + TACC3 FusionTACC3 CCDC61
Erdafitinib	Adrenal CarcinomaUNRESOLVED	Predictive	C	Supports Sensitivity Response	3	accepted	EID4861 Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 4 … (full text at CIViC) PMID 26324363 · Tabernero et al., 2015 · Open in CIViC	civic

CCDC6 Fusion + TACC3 FusionTACC3 CCDC61

Erdafitinib

Adrenal CarcinomaUNRESOLVED

Predictive

Supports Sensitivity Response

accepted

EID4861

PMID 26324363 · Tabernero et al., 2015 · Open in CIViC

civic

FGFR3 N540K + TACC3 FusionTACC3 FGFR31
Erdafitinib + FutibatinibSubstitutes	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	3	accepted	EID12706 Ba/F3 cells expressing the FGFR3::TACC3 fusion with or without the N540K mutation were treated with multiple FGFR inhibitors, including erdafitinib and futibatinib. In parental Ba/F3 cells, the IC50 v… (full text at CIViC) PMID 37377403 · Facchinetti et al., 2023 · Open in CIViC	civic

FGFR3 N540K + TACC3 FusionTACC3 FGFR31

Erdafitinib + FutibatinibSubstitutes

Malignant NeoplasmALIAS

Predictive

Supports Resistance

accepted

EID12706

Ba/F3 cells expressing the FGFR3::TACC3 fusion with or without the N540K mutation were treated with multiple FGFR inhibitors, including erdafitinib and futibatinib. In parental Ba/F3 cells, the IC50 v… (full text at CIViC)

PMID 37377403 · Facchinetti et al., 2023 · Open in CIViC

civic